Amgen’s Repatha (evolocumab) Receives NMPA (CFDA) Approval for Reduction of Cardiovascular Risks in China

 Amgen’s Repatha (evolocumab) Receives NMPA (CFDA) Approval for Reduction of Cardiovascular Risks in China

Amgen’s Repatha (evolocumab) Receives NMPA (CFDA) Approval for Reduction of Cardiovascular Risks in China

Shots:

  • The expanded indication approval is based on the results of P-III FOURIER study assessing Repatha (140mg q2w, 420 mg/month) vs PBO + statin therapy in patients with cardiovascular events
  • The study resulted in a reduction in risk of heart attack by 27%, risk of stroke by 21%, the risk of coronary revascularization by 22% and an overall reduction in cardiovascular events with safe and efficate results
  • Repatha (evolocumab) is a mAb that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) and received NMPA approval on 31 Jul, 2018 for homozygous familial hypercholesterolemia (HoFH) in adults

Click Here  read full press release/ article | Ref: Press Reader | Image: Pic Sunday

 

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post